Insmed Inc (INSM) Stock Price, Quote & News

Company Profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 977 9900

Website: www.insmed.com

Address:

700 US Highway 202/206, Bridgewater, United States

OfficialStocktwitsUser Feb. 3 at 7:46 PM

$INSM RSI: 42.10, MACD: -6.2584 Vol: 6.96, MA20: 162.64, MA50: 180.16 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

kelrock90 Feb. 3 at 5:07 PM

$INSM ENCORE Trial Reaches Key Milestone in MAC Lung Infection https://clinicaltrials.gov/study/NCT04677569?term=MAC&intr=arikayce&rank=5

2 · Reply

pianoman439 Jan. 30 at 5:34 PM

$INSM real generous of you Matthew! Insmed (NASDAQ:INSM) had its price target raised by Morgan Stanley (analyst Matthew Harrison) from $157.00 to $162.00. They now have an "equal weight" rating on the stock. This represents a 3.0% upside from the current price of $157.34.

1 · Reply

RunnerSignals Jan. 29 at 10:07 PM

Is your portfolio ready for 94% upside? $CRCL $APLS $AMPX $INSM $GRAB are flashing huge buy signals https://stocksrunner.com/news/2026-01-29-today-stock-upgrade-analysis

1 · Reply

IN0V8 Jan. 29 at 4:32 PM

$INSM 1/28/26 Buy Barclays initiates coverage with overweight rating and target $231

0 · Reply

pianoman439 Jan. 29 at 3:28 PM

$INSM Insmed (NASDAQ:INSM) was upgraded by Barclays PLC (analyst Eliana Merle) to a "strong-buy" rating.The current price is $155.89.

1 · Reply

bemore Jan. 29 at 2:01 AM

$INSM Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress today announced that it will present four abstracts on treprostinil palmitil inhalation powder (TPIP) at the Pulmonary Vascular Research Institute (PVRI) 2026 congress in Dublin from January 28 – February 1, 2026.

0 · Reply

free2dream Jan. 28 at 6:13 PM

$SRPT sarepta pre announced $400M quarter and close to $1B cash position. The market cap is $2B ! Let's see some comps $INSM $35B market cap, $400M ANNUAL SALES. $DYN $3B market cap, no sales, $WVE $2.5B market cap $100M annual sales I can go on. Sarepta is extremely undervalued to just about anything. Algos holding this up, the gap up is coming at some point.

0 · Reply

kelrock90 Jan. 28 at 3:05 PM

$INSM https://investor.insmed.com/2026-01-28-Insmed-to-Present-Multiple-Abstracts-on-Treprostinil-Palmitil-Inhalation-Powder-TPIP-at-Pulmonary-Vascular-Research-Institute-PVRI-2026-Congress

0 · Reply

bemore Jan. 28 at 1:52 PM

$INSM Barclays Initiates Coverage Overweight Rating, $231 Price Target

0 · Reply

Insmed: A Brensocatib Pipeline Setback Is Masking A Dupixent-Like Launch

Jan 29, 2026, 9:39 AM EST - 5 days ago

Artisan Global Opportunities Fund Q4 2025 Portfolio Update

ARGX BKR BSX COF COIN LEG LHX

Jan 28, 2026, 7:00 AM EST - 6 days ago

Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress

Jan 23, 2026, 9:08 AM EST - 11 days ago

Artisan Small Cap Fund Q4 2025 Portfolio Activity

BRKR CLBT FLEX GH HXL IRTC ITGR

Jan 19, 2026, 10:30 PM EST - 14 days ago

Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity

ALAB ARGX COHR CRM CVNA DASH FERG

Jan 12, 2026, 8:16 PM EST - 22 days ago

Insmed Incorporated (INSM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 6:14 PM EST - 22 days ago

Insmed CEO Will Lewis talks its rare disease drug pipeline

Jan 9, 2026, 10:58 AM EST - 25 days ago

Insmed Maps Aggressive 2026 As Newly Approved Lung Disease Drug Gains Traction, Pipeline Advances

Jan 9, 2026, 7:00 AM EST - 25 days ago

Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 2, 2026, 7:00 AM EST - 4 weeks ago

Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 29, 2025, 9:29 PM EST - 5 weeks ago

INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm

Dec 18, 2025, 6:09 PM EST - 6 weeks ago

Mizuho's Jared Holz talks Insmed sinking double digits on sinus drug trial news

Dec 18, 2025, 12:30 PM EST - 6 weeks ago

Why Is Insmed Stock Falling Thursday?

Dec 18, 2025, 8:04 AM EST - 6 weeks ago

Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

BIRK

Dec 18, 2025, 7:12 AM EST - 6 weeks ago

Insmed Stock Plummets 19%. This Is What Sparked the Selloff.

Dec 18, 2025, 7:00 AM EST - 6 weeks ago

Top 3 Health Care Stocks You'll Regret Missing This Quarter

LEGN TEM

Dec 17, 2025, 5:35 PM EST - 6 weeks ago

Insmed scraps development of sinus drug after mid-stage study failure

Dec 17, 2025, 4:01 PM EST - 6 weeks ago

Insmed Provides Clinical and Business Update

Dec 11, 2025, 10:37 AM EST - 7 weeks ago

Eight stock picks to play one of the healthiest corners of the market

ALNY ASND MASI NTRA PODD UNH WGS

Dec 4, 2025, 7:00 AM EST - 2 months ago

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Dec 2, 2025, 12:53 PM EST - 2 months ago

Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript

Nov 20, 2025, 3:45 PM EST - 2 months ago

These 15 stocks are still showing momentum — and a market-beating edge

BE CIEN CRDO GH LITE MP MU

Nov 18, 2025, 11:00 AM EST - 2 months ago

European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

Nov 18, 2025, 5:48 AM EST - 2 months ago

Insmed Incorporated (INSM) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 13, 2025, 7:00 AM EST - 2 months ago

Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

Nov 6, 2025, 8:10 AM EST - 3 months ago

Artisan Global Opportunities Fund Q3 2025 Portfolio Update

AMZN BSX DKS LHX SPOT TEAM VRTX

Nov 5, 2025, 8:10 AM EST - 3 months ago

American Century Focused Dynamic Growth Fund Q3 2025 Performance Contributors And Detractors

AAPL ALNY APP CMG GOOGL NFLX STZ

Nov 5, 2025, 7:00 AM EST - 3 months ago

Insmed To Present at November and December 2025 Investor Conferences

Nov 3, 2025, 6:13 PM EST - 3 months ago

Latest read on rare disease gene therapy from Insmed CEO Will Lewis

Oct 30, 2025, 11:16 AM EDT - 3 months ago

Insmed Incorporated (INSM) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:00 AM EDT - 3 months ago

Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update

Oct 27, 2025, 1:27 PM EDT - 3 months ago

Baron Health Care Fund Q3 2025 Top Contributors And Detractors

ARGX BSX ISRG LLY RDNT

Oct 23, 2025, 4:05 PM EDT - 3 months ago

Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List

Oct 17, 2025, 7:00 AM EDT - 3 months ago

CHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

Oct 16, 2025, 7:00 AM EDT - 3 months ago

Insmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

Oct 15, 2025, 7:00 AM EDT - 3 months ago

Insmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025

Sep 30, 2025, 2:33 PM EDT - 4 months ago

Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality

Sep 22, 2025, 7:00 AM EDT - 4 months ago

Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

Sep 10, 2025, 12:10 PM EDT - 5 months ago

Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 5, 2025, 10:49 AM EDT - 5 months ago

Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 21, 2025, 7:00 AM EDT - 5 months ago

Insmed To Present at September Investor Conferences

Aug 20, 2025, 2:46 PM EDT - 5 months ago

Lung Disease-Focused Insmed 'Must-Own' Name For Investors

Aug 19, 2025, 1:04 PM EDT - 6 months ago

Josh Brown's Best Stocks in the Market: Insmed

Aug 13, 2025, 6:15 PM EDT - 6 months ago

Insmed CEO on what's next for company after FDA greenlights lung disease drug

Aug 12, 2025, 2:20 PM EDT - 6 months ago

FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease

Aug 12, 2025, 11:42 AM EDT - 6 months ago

US FDA approves Insmed's lung disease drug

Aug 12, 2025, 11:34 AM EDT - 6 months ago

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Aug 7, 2025, 10:20 PM EDT - 6 months ago

Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 9:35 PM EDT - 6 months ago

Baron Health Care Fund Q2: Top Contributors, Misses, And Strategic Shifts

ARGX COO ELV HQY IDXX ISRG RDNT

OfficialStocktwitsUser Feb. 3 at 7:46 PM

0 · Reply

kelrock90 Feb. 3 at 5:07 PM

$INSM ENCORE Trial Reaches Key Milestone in MAC Lung Infection https://clinicaltrials.gov/study/NCT04677569?term=MAC&intr=arikayce&rank=5

2 · Reply

pianoman439 Jan. 30 at 5:34 PM

1 · Reply

RunnerSignals Jan. 29 at 10:07 PM

Is your portfolio ready for 94% upside? $CRCL $APLS $AMPX $INSM $GRAB are flashing huge buy signals https://stocksrunner.com/news/2026-01-29-today-stock-upgrade-analysis

1 · Reply

IN0V8 Jan. 29 at 4:32 PM

$INSM 1/28/26 Buy Barclays initiates coverage with overweight rating and target $231

0 · Reply

pianoman439 Jan. 29 at 3:28 PM

$INSM Insmed (NASDAQ:INSM) was upgraded by Barclays PLC (analyst Eliana Merle) to a "strong-buy" rating.The current price is $155.89.

1 · Reply

bemore Jan. 29 at 2:01 AM

0 · Reply

free2dream Jan. 28 at 6:13 PM

0 · Reply

kelrock90 Jan. 28 at 3:05 PM

$INSM https://investor.insmed.com/2026-01-28-Insmed-to-Present-Multiple-Abstracts-on-Treprostinil-Palmitil-Inhalation-Powder-TPIP-at-Pulmonary-Vascular-Research-Institute-PVRI-2026-Congress

0 · Reply

bemore Jan. 28 at 1:52 PM

$INSM Barclays Initiates Coverage Overweight Rating, $231 Price Target

0 · Reply

SuperGreenToday Jan. 28 at 2:36 AM

$INSM Share Price: $162.70 Contract Selected: May 15, 2026 $165 Calls Buy Zone: $13.60 – $16.80 Target Zone: $24.50 – $29.95 Potential Upside: 70% ROI Time to Expiration: 107 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

pianoman439 Jan. 27 at 11:03 PM

$INSM Insmed (NASDAQ:INSM) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.The current price is $162.64.

0 · Reply

JFais Jan. 27 at 12:48 PM

$LQDA (L @ 7% PW, +88% gain) For those claiming that $INSM's TPIP is unequivocally better (no room for the possibility of being wrong) First post is from my entry, 2nd is my JPM notes Both help me hold my remaining shares patiently (after partial profits ahead of the binary)

1 · Reply

JoeB07 Jan. 26 at 10:51 PM

$GIFI $INSM $SKYT now 2/3 have been bought out. $INSM buyout coming soon!? What say you $GS ?$?$?$

1 · Reply

pianoman439 Jan. 23 at 3:36 PM

$INSM Roth has initiated Insmed (INSM) at buy saying it sees above consensus sales of Brinsupri (brensocatib) and Arikayce (amikacin liposome inhalation suspension). The firm set a $212 price target (~32% upside based on Jan. 22 close). Analyst Adam Walsh sees Brinsupri peak sales of $8.1B and for Arikayce, $1.3B. Walsh also highlighted the potential of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension given positive mid-stage trial results released in June 2025. He sees $5B probability of success-adjusted peak sales.

1 · Reply

pianoman439 Jan. 22 at 10:15 PM

$INSM Insmed (NASDAQ:INSM) is now covered by analysts at Roth Mkm. They set a "buy" rating on the stock.

1 · Reply

free2dream Jan. 21 at 10:33 PM

$MRNA great run and it is still below 20B market cap. This can still double or triple from here. $SRPT however might be a better play, still only $2B market cap and 400m revenue per each quarter is absolutely amazing vs something like $INSM valued at 33B . Sarepta is extremely undervalued.

0 · Reply

Mcnastyy Jan. 21 at 7:39 PM

$INSM damn does this shit ever stop bleeding every pop seems to get ripped back down

0 · Reply

Quantumup Jan. 21 at 7:36 PM

RBC Capital⬆️ $INSM's PT to $200 from $197 and reiterated at an Outperform rating. $LQDA $UTHR Here's what RBC Capital said in its note: https://x.com/Quantumup1/status/2014058530009993526?s=20

0 · Reply

SuperGreenToday Jan. 20 at 9:40 PM

$INSM Share Price: $163.51 Contract Selected: May 15, 2026 $165 Calls Buy Zone: $12.58 – $15.54 Target Zone: $23.95 – $29.28 Potential Upside: 80% ROI Time to Expiration: 114 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

free2dream Jan. 20 at 5:39 PM

$SRPT extremely UNDERVALUED, not sure how long will the algos keep it trapped down here. The rebound will be significant. This should be valued higher than $INSM

0 · Reply

smartkarma Jan. 20 at 12:33 AM

$INSM | Insmed Inc (INSM US): Brinsupri on High Trajectory; Multiple Readouts to Make 2026 a Pivotal Year "Insmed recorded $145M revenue from Brinsupri in 4Q25. Ongoing U.S. launch of Brinsupri and geography expansion, label expansion of Arikayce, and trial readouts will drive Insmed performance." - Tina Banerjee Read more: https://www.smartkarma.com/insights/insmed-inc-insm-us-brinsupri-on-high-trajectory-multiple-readouts-to-make-2026-a-pivotal-year

0 · Reply

Market Cap	33.46B
Revenue (ttm)	363.71M
Net Income (ttm)	-913.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-251.24%
Debt to Equity Ratio	0.57

Volume	2,484,100
Avg Vol	3,282,106
Day's Range	N/A - N/A
Shares Out	213.27M
Stochastic %K	43%
Beta	1.08
Analysts	Strong Sell
Price Target	$215.35